Iovance Biotherapeutics Inc (NAS:IOVA)
$ 7.78 -0.36 (-4.42%) Market Cap: 2.18 Bil Enterprise Value: 2.01 Bil PE Ratio: 0 PB Ratio: 3.20 GF Score: 35/100

Iovance Biotherapeutics Inc Corporate Call Transcript

Jan 23, 2023 / 01:30PM GMT
Release Date Price: $7 (+11.64%)
Operator

Welcome to the Iovance Biotherapeutics Special Update Conference Call. My name is Michelle, and I will be your operator for today's call.

At this time, all participants are in listen only mode. Later, we will conduct a question-and-answer session. (Operator Instructions) Please note that this conference is being recorded.

I will now turn the call over to Sara Pellegrino, Senior Vice President, Investor Relations and Corporate Communications at Iovance. Sara, please begin.

Sara Pellegrino
Iovance Biotherapeutics, Inc. - VP of IR & Public Relations

Thank you, operator. Good morning, and thank you for joining our conference call to discuss recent corporate, clinical and regulatory updates. These updates were highlighted in a press release we issued earlier this morning, which can also be found on our corporate website at iovance.com.

On today's call, Dr. Fred Vogt, our Interim President and Chief Executive Officer, will provide a brief introduction and summary about our acquisition of Proleukin, a recombinant human interleukin-2

Already have an account? Log in
Get the full story
Access to All Earning Calls and Stock Analysis
30-Year Financial on one screen
All-in-one Stock Screener with unlimited filters
Customizable Stock Dashboard
Real Time Insider Trading Transactions
8,000+ Institutional investors’ 13F holdings
Powerful Excel Add-in and Google sheets Add-on
All data downloadable
Quick customer support
And much more...
30-Day 100% money back guarantee
You are not charged until the trial ends. Subscription fee may be tax deductible.
Excellent
4.6 out of 5 Trustpilot